FYARRO vs KISQALI

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 21, 2026·How we rate

Possible drug interaction. FYARRO and KISQALI are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	FYARRO	KISQALI
Rating	New	70/100
Pharmacy pays	~$48.61 /30	—
Type	RX	RX
Active ingredient	SIROLIMUS	RIBOCICLIB SUCCINATE
Manufacturer	Aadi	Novartis
Dosage forms	Injectable	Tablet
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	None	None
Treats	Lymphangioleiomyomatosis, Perivascular Epithelioid Cell Neoplasms	Breast Neoplasms

fyarro kisqali

Rating

New

70/100

Pharmacy pays

~$48.61 /30

—

Type

Active ingredient

SIROLIMUS

RIBOCICLIB SUCCINATE

Manufacturer

Aadi

Novartis

Dosage forms

Injectable

Tablet

Drug class

Kinase Inhibitor

Boxed warning

None

Treats

Lymphangioleiomyomatosis, Perivascular Epithelioid Cell Neoplasms

Breast Neoplasms

Frequently asked questions

What is the difference between Fyarro and Kisqali?

Fyarro contains Sirolimus, while Kisqali contains Ribociclib Succinate — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.